Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Granisetron
Drug ID BADD_D01040
Description A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Indications and Usage For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
Marketing Status approved; investigational
ATC Code A04AA02
DrugBank ID DB00889
KEGG ID D04370
MeSH ID D017829
PubChem ID 5284566
TTD Drug ID D0J5KF
NDC Product Code 14778-0202; 47426-101; 63850-7308; 42747-726; 53104-7609; 55111-841; 55718-117; 54871-1091
UNII WZG3J2MCOL
Synonyms Granisetron | 1-Methyl-N-(endo-9-Methyl-9-Azabicyclo(3.3.1)non-3-yl)-1H-Indazole-3-Carboxamide | Kytril | BRL-43694A | BRL 43694A | BRL43694A | BRL-43694 | BRL 43694 | BRL43694 | Granisetron Hydrochloride | Hydrochloride, Granisetron | Granisetron Monohydrochloride | Monohydrochloride, Granisetron
Chemical Information
Molecular Formula C18H24N4O
CAS Registry Number 109889-09-0
SMILES CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.010534%
Abdominal pain07.01.05.002--
Agitation19.06.02.001; 17.02.05.012--
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Anxiety19.06.02.002--
Application site erythema08.02.01.001; 23.03.06.005; 12.07.01.0010.108850%Not Available
Application site irritation12.07.01.003; 08.02.01.0030.046679%Not Available
Application site pain12.07.01.004; 08.02.01.0040.024579%Not Available
Application site pruritus12.07.01.005; 08.02.01.005; 23.03.12.0040.108850%Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.0160.099349%Not Available
Application site reaction12.07.01.006; 08.02.01.0060.017556%Not Available
Application site warmth12.07.01.029; 08.02.01.0290.007023%Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Burning sensation17.02.06.001; 08.01.09.0290.010534%Not Available
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Coagulation time prolonged13.01.02.006--Not Available
Colitis07.08.01.0010.008055%
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene